Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X about a paper by John Heymach et al. published in the Journal of Clinical Oncology:

“Out in Journal of Clinical Oncology – Phase 1a study of zongertinib in metastatic solid tumors with HER2 alterations:

54 NSCLC patients
ORR 35%, DCR 93%
PFS 17.2 mos
Diarrhea most common AE (50%, most grade 1/2)
Expansion doses: 120/240mg QD

Timely as U.S. FDA granted priority review <2 weeks ago!”

“HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

Authors: John Heymach, Frans Opdam, Minal Barve, Kiyotaka Yoh, Noboru Yamamoto et al.

Eric Singhi: Phase 1a study of zongertinib in metastatic solid tumors with HER2 alterations